how we devise new treatment strategies for those patients with tumour progression on platinum therapy.Platinum-non-eligible ovarian cancer is treated with single-agent non-platinum drugs.When bevacizumab can be added to chemotherapy,progression-free survival improves significantly.For patients with a BRCA...
Patients with ovarian cancer who have progressed after first-line platinum-based chemotherapy after less than 6 months of treatment are considered as having platinum-resistant disease, states Robert L. Coleman, MD. Individuals who progress after 12 months have platinum-sensitive disease, and individuals...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospe...
The objective was to determine the response rate to platinum retreatment of "platinum-resistant" ovarian cancer after intervening nonplatinum therapy. We retrospectively identified 30 patients with platinum-resistant ovarian cancer who received nonplatinum chemotherapy for recurrent epithelial ovarian cancer pr...
However, to date, no study supported the adoption of immunotherapy in platinum-resistant ovarian cancer. In this regard there are several aspects that need further investigation. It is well know that the use of immunotherapy requires the contribution of three major players: the tumor, the immune ...
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy 来自 Semantic Scholar 喜欢 0 阅读量: 61 作者: Amber Klein a,Xiaoying He a,Maria Roche a,Allison Mallett a,Linda Duska b,Jeffrey G. Supko a,Michael V. Seiden a 展开 ...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), trea
(e.g., testicular, ovarian, and lung cancer). Exposure of platinum-based drugs to the tumor over extended periods of time can lead to resistance formation. Various molecular and cellular mechanisms of action contribute to a resistant phenotype. Chemotherapy resistance finally forms a major hurdle ...
Ovarian cancer is a prevalent gynecologic malignancy with the second-highest mortality rate among gynecologic malignancies. Platinum-based chemotherapy is the first-line treatment for ovarian cancer; however, a majority of patients with ovarian cancer ex
In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is the first randomized phase III trial to our knowledge combining bevacizumab with chemotherapy in platinum-resistant OC. 关键词: Humans Ovarian Neoplasms Neoplasm ...